UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Incentives for promoting Battery Electric Vehicle (BEV) adoption in Norway

Transportation research. Part D, Transport and environment, 2016-03, Vol.43, p.169-180

2016

Link zum Volltext

Verfügbarkeit prüfen

IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.538-538

2023

Link zum Volltext

Verfügbarkeit prüfen

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

Annals of oncology, 2018-10, Vol.29, p.viii714-viii715

2018

Link zum Volltext

Verfügbarkeit prüfen

BEV-CFKT: A LiDAR-camera cross-modality-interaction fusion and knowledge transfer framework with transformer for BEV 3D object detection

Neurocomputing (Amsterdam), 2024-05, Vol.582, Article 127527

2024

Link zum Volltext

Verfügbarkeit prüfen

Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment

Breast cancer research and treatment, 2022-11, Vol.196 (2), p.423-437

2022

Link zum Volltext

Verfügbarkeit prüfen

Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2022-2022

2023

Link zum Volltext

Verfügbarkeit prüfen

Is government R&D subsidy good for BEV supply chain? The challenge from downstream competition

Computers & industrial engineering, 2022-03, Vol.165, p.107951, Article 107951

2022

Link zum Volltext

Verfügbarkeit prüfen

Can China’s BEV market sustain without government subsidies?: An explanation using cues utilization theory

Journal of cleaner production, 2020-11, Vol.272, p.122589, Article 122589

2020

Link zum Volltext

Verfügbarkeit prüfen

Modeling the charging and route choice behavior of BEV drivers

Transportation research. Part C, Emerging technologies, 2016-04, Vol.65, p.190-204

2016

Link zum Volltext

Verfügbarkeit prüfen

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9002-9002

2018

Link zum Volltext

Verfügbarkeit prüfen

GIS-Based Probabilistic Modeling of BEV Charging Load for Australia

IEEE transactions on smart grid, 2019-07, Vol.10 (4), p.3525-3534

2019

Link zum Volltext
Volltext

To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy?

Cancers, 2023-05, Vol.15 (11), p.2980

Sznurkowski, Jacek Jan

2023

Link zum Volltext

Verfügbarkeit prüfen

Existence Is Resistance: A Reflection on Beverly 'Bev' Ditsie's Fashion Performativity

Biography (Honolulu), 2022-06, Vol.45 (3), p.249-270

2022

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.8-8

2022

Link zum Volltext

Verfügbarkeit prüfen

FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial

Annals of oncology, 2016-10, Vol.27, p.vi560-vi560

2016

Link zum Volltext

Verfügbarkeit prüfen

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS mutant unresectable colorectal liver-limited metastases: A study protocol of a multicenter randomized controlled phase 3 (BECOME2) trial

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS228-TPS228

2022

Link zum Volltext

Verfügbarkeit prüfen

Generating evidential BEV maps in continuous driving space

ISPRS journal of photogrammetry and remote sensing, 2023-10, Vol.204, p.27-41

2023

Link zum Volltext

Verfügbarkeit prüfen

Electrification of the two-car household: PHEV or BEV?

Transportation research. Part C, Emerging technologies, 2017-12, Vol.85, p.363-376

2017

Link zum Volltext

Verfügbarkeit prüfen

Bev Said “No”: Learning From Nursing Home Residents About Care Politics in Our Aging Society

The Gerontologist, 2023-12, Vol.63 (10), p.1663-1671

2023

Link zum Volltext

Verfügbarkeit prüfen

Examining BEV Drivers’ Willingness to Share Personal Information in the Context of Smart Charging: Results of a Five-Month BEV Field Trail

Transportation research procedia (Online), 2023, Vol.70, p.330-337

2023

Link zum Volltext

Verfügbarkeit prüfen

Monocular BEV Perception of Road Scenes Via Front-to-Top View Projection

IEEE transactions on pattern analysis and machine intelligence, 2024-03, Vol.PP

2024

Link zum Volltext

Verfügbarkeit prüfen

FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO

Annals of oncology, 2018-06, Vol.29, p.v106-v106

2018

Link zum Volltext

Verfügbarkeit prüfen

615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery

Annals of oncology, 2022-09, Vol.33, p.S826

2022

Link zum Volltext

Verfügbarkeit prüfen

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.140-140

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 73.759

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29.016)
Mit Volltextzugriff
(51.861)

Publikationsform

11 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(69.821)
Deutsch
(2.577)
Japanisch
(2.327)
Norwegisch
(682)
Italienisch
(643)
Französisch
(571)
Bokmål, Norwegian; Norwegian Bokmål
(224)
Spanisch
(133)
Portugiesisch
(108)
Ungarisch
(95)
Niederländisch
(81)
Latein
(45)
Chinesisch
(34)
Dänisch
(29)
Polnisch
(28)
Türkisch
(28)
Tschechisch
(26)
Koreanisch
(25)
Slowakisch
(22)
Slowenisch
(19)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(17.517)
Life Sciences & Biomedicine
(10.538)
Electric Vehicles
(6.440)
Technology
(6.216)
Humans
(5.798)
Physical Sciences
(3.079)
Oncology
(2.944)
Engineering
(2.937)
Social Sciences
(2.801)
Female
(2.658)
Automobile Industry
(2.440)
Male
(2.247)
Forecasts And Trends
(2.103)
Batteries
(2.060)
Automobiles
(1.890)
Animals
(1.686)
Energy & Fuels
(1.681)
Emissions
(1.675)
Bevacizumab
(1.669)
Environmental Sciences & Ecology
(1.626)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Nexis Uni
(18.537)
Factiva
(15.931)
EZB Electronic Journals Library
(15.338)
IngentaConnect
(12.161)
NUS Single-Journal Subscriptions
(8.437)
EBSCOhost Business Source Ultimate
(8.016)
IngentaConnect Journals
(6.393)
Journals@Ovid Full Text
(6.304)
Ebook Central Perpetual and DDA
(4.299)
eBooks on EBSCOhost
(4.269)
SpringerNature Journals
(3.933)
Wiley Online Library
(3.819)
JSTOR Complete Journals
(3.613)
Elsevier ScienceDirect Journals Complete
(2.726)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.403)
Wiley Online Library Full Collection 2018
(2.130)
Springer Books
(2.019)
Taylor & Francis Journals Complete
(1.845)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.703)
SAGE Complete
(1.689)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Incentives for promoting Battery Electric Vehicle (BEV) adoption in Norway

IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

BEV-CFKT: A LiDAR-camera cross-modality-interaction fusion and knowledge transfer framework with transformer for BEV 3D object detection

Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment

Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM)

Is government R&D subsidy good for BEV supply chain? The challenge from downstream competition

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

Can China’s BEV market sustain without government subsidies?: An explanation using cues utilization theory

Modeling the charging and route choice behavior of BEV drivers

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC

GIS-Based Probabilistic Modeling of BEV Charging Load for Australia

To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy?

Existence Is Resistance: A Reflection on Beverly 'Bev' Ditsie's Fashion Performativity

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS mutant unresectable colorectal liver-limited metastases: A study protocol of a multicenter randomized controlled phase 3 (BECOME2) trial

Generating evidential BEV maps in continuous driving space

Electrification of the two-car household: PHEV or BEV?

Bev Said “No”: Learning From Nursing Home Residents About Care Politics in Our Aging Society

Examining BEV Drivers’ Willingness to Share Personal Information in the Context of Smart Charging: Results of a Five-Month BEV Field Trail

Monocular BEV Perception of Road Scenes Via Front-to-Top View Projection

FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO

615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev

Suchergebnisse filtern